Business & Industry
- Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
- Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'
- Pfizer's Phase 2 study of trispecific antibody positive in moderate to severe atopic dermatitis
- U.S. FDA grants full approval to Pfizer's BRAFTOVI combination regimen in first-line metastatic colorectal cancer
- Pfizer launches cost savings program on TrumpRx lowering drug costs for millions of Americans
Research & Development
- Plastic bottles transformed into Parkinson’s drug using bacteria
- Researchers break decades-old bottleneck in chemotherapy drug manufacturing
- Preclinical study reveals new cream may prevent or slow growth of some common skin cancers
- Safer blood clot treatment with apixaban than with rivaroxaban
- Experimental chemo drug may trick the immune system into fighting cancer
- New drug combination doubles down on Alzheimer's treatments
- Life-changing drug identified for children with rare epilepsy
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA expands artificial intelligence capabilities with agentic AI deployment
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis